Insmed Inc. (INSM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$126.29-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INSM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 1,137.6 | 606.4 | 363.7 | 305.2 | 245.4 | 188.5 | 164.4 | 136.5 | 9.8 | 0.0 | — | 11.5 | 11.5 | 11.5 | 0.0 | 4.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.0 | — | 11.5 | 11.5 | 11.5 | 0.0 | 4.4 |
| Cost of Revenues | 188.2 | 122.9 | 85.7 | 65.6 | 55.1 | 44.2 | 39.9 | 24.2 | 2.4 | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | 112.3 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 893.6 | 701.2 | 461.1 | 344.5 | 265.8 | — | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 860.8 | 771.1 | 598.4 | 571.0 | 397.5 | 272.7 | 181.2 | 131.7 | 145.3 | 109.7 | 122.7 | 74.3 | 56.3 | 44.3 | 29.8 | 28.6 |
| Operating Income | (840.6) | (1,246.8) | (878.3) | (709.6) | (457.3) | (375.1) | (265.2) | (235.2) | (307.3) | (188.9) | (173.4) | (117.5) | (87.4) | (55.0) | (42.4) | (61.7) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 83.8 | 84.9 | 81.7 | 26.4 | 40.5 | 29.6 | 27.7 | 25.5 | 5.9 | 3.5 | 2.9 | 2.4 | 2.4 | 0.8 | 0.0 |
| Interest & Investment Income | 56.5 | 60.7 | 53.3 | 42.1 | 11.1 | 0.2 | 1.7 | 9.9 | 10.3 | 1.6 | 0.6 | 0.3 | 0.1 | 0.2 | 1.8 | 2.1 |
| Net Interest Expenses | — | — | — | 39.6 | 15.4 | 40.3 | 27.9 | 17.8 | 15.1 | 4.3 | 2.9 | 2.6 | 2.4 | 2.2 | (1.1) | (2.1) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | 26.0 | 0.0 | 26.0 |
| EBT, Incl. Unusual Items | (869.1) | (1,271.7) | (910.1) | (747.0) | (480.2) | (436.4) | (292.7) | (253.6) | (324.1) | (192.9) | (176.2) | (120.2) | (89.6) | (57.3) | (41.4) | (59.7) |
| Income Tax Expense | 6.2 | 5.0 | 3.7 | 2.6 | 1.4 | (1.8) | 1.4 | 0.8 | 0.2 | (0.3) | 0.1 | (2.0) | (10.4) | (1.2) | 0.0 | 0.0 |
| Net Income | ||||||||||||||||
| Net Income | (875.3) | (1,276.8) | (913.8) | (749.6) | (481.5) | (434.7) | (294.1) | (254.3) | (324.3) | (192.6) | (176.3) | (118.2) | (79.2) | (56.1) | (41.4) | (59.7) |
| Per Share | ||||||||||||||||
| Basic EPS | (4.03) | (6.42) | (5.57) | (5.34) | (3.91) | (3.88) | (3.01) | — | — | — | — | — | — | — | — | (2.95) |
| Diluted EPS | (4.03) | (6.42) | (5.57) | (5.34) | (3.91) | (3.88) | (3.01) | — | — | — | — | — | — | — | — | (2.95) |
| Revenue per Share | 5.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 217.4 | 199.0 | 164.0 | 140.4 | 123.0 | 112.1 | 97.6 | 84.6 | 76.9 | 66.6 | 61.9 | 58.6 | 43.1 | 35.0 | 26.5 | 23.3 |
| Diluted Weighted Avg Shares | 217.4 | 199.0 | 164.0 | 140.4 | 123.0 | 112.1 | 97.6 | 84.6 | 76.9 | 66.6 | 61.9 | 58.6 | 43.1 | 35.0 | 26.5 | 23.3 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | (704.1) | (452.0) | (366.0) | (256.1) | (230.0) | (303.7) | (186.0) | (171.0) | (115.5) | (86.3) | (54.3) | (41.9) | (61.4) |
| EBIT | (840.6) | (1,246.8) | (878.3) | (709.6) | (457.3) | (375.1) | (265.2) | (235.2) | (307.3) | (188.9) | (173.4) | (117.5) | (87.4) | (55.0) | (42.4) | (61.7) |
| Effective Tax Rate | -0.7% | — | — | -0.3% | -0.3% | 0.4% | -0.5% | -0.3% | -0.1% | 0.1% | -0.1% | 1.6% | 11.6% | 2.1% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.